<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715375</url>
  </required_header>
  <id_info>
    <org_study_id>U44-CRE-01</org_study_id>
    <secondary_id>U44AI074918</secondary_id>
    <nct_id>NCT02715375</nct_id>
  </id_info>
  <brief_title>Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma</brief_title>
  <acronym>CREON2000A</acronym>
  <official_title>A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Innovations and Goods, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bernstein Clinical Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>General Innovations and Goods, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pivotal, 12-month, randomized, sham controlled, parallel group, multicenter, double
      blind study with an allocation ratio of 1:1. The study population is children between the
      ages 6 to 17 years, with mild to moderate persistent asthma. The purpose of the study is to
      determine whether the CREON2000A, an environmental control device, will decrease asthma
      severity, as measured by the Composite Asthma Severity Index (CASI), in children with mild to
      moderate persistent allergic asthma over a twelve month period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pilot study (Protocol #PA-01-052; Health Effects of CREON2000 in Asthmatic Children. IB
      ID# GI 1001) offered preliminary evidence that the CREON2000A system may be beneficial in
      asthma. This study is a follow-up, using children, aged 6 to 17 with mild to moderate
      persistent asthma, as the subjects of the study. Children are usually treated with fewer
      controller medications and have fewer confounding co-morbidities making it more likely to
      detect a therapeutic benefit from an environmental intervention. The study will involve 4
      study site visits, 2 home visits, and 7 phone calls. Adjustment of asthma therapy by the site
      clinician will occur at baseline (Visit 1) and at each follow-up office visit after Visit 1
      using a modified algorithm based on the National Asthma Education and Prevention Program
      Expert Panel Report 3 (NAEPP EPR3) guidelines. Enrollment will be over 18 months. The study
      duration for each subject will be 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CASI Score</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Difference between study arms in the change in asthma severity as measured by the Composite Asthma Severity Index (CASI) from Baseline (Visit 1) to the 12-month follow up office visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume (FEV1)</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>• in the mean change in FEV1 (% predicted) from Baseline (Visit 1) to 12-month follow up office visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in number of day time symptom scores</measure>
    <time_frame>Baseline, 4, 8 and12 months</time_frame>
    <description>• in the mean change in number of day time symptom scores from Baseline (Visit 1) to the 4, 8 and 12-month follow up office visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in number of night time symptoms</measure>
    <time_frame>Baseline, 4, 8 and 12 months</time_frame>
    <description>• in the mean change in number of night time symptom scores from Baseline (Visit 1) to the 4, 8 and 12-month follow up office visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the number of daily puffs/inhalations of short-acting beta-agonist (SABA) rescue medication</measure>
    <time_frame>Baseline, 4, 8 and 12 months</time_frame>
    <description>• in the mean change in the number of daily puffs/inhalations of short-acting beta-agonist rescue medication taken over 14 days prior to each evaluation, from Baseline (Visit 1) to 4, 8 and 12 month follow up office visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in CASI</measure>
    <time_frame>Baseline, 4, 8 and 12 months</time_frame>
    <description>• in the mean change in CASI from Baseline (Visit 1) to 4- and 8- and 12-month follow up office visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in daily does of inhaled glucocorticoids taken (µg/day)</measure>
    <time_frame>Baseline 4, 8 and 12 months</time_frame>
    <description>• in the mean change in daily dose of inhaled glucocorticoids taken (µg/day) by participants from Baseline (Visit 1) to 4, 8 and 12 months follow up office visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the percentage of patients with an asthma exacerbation</measure>
    <time_frame>Baseline and12 months</time_frame>
    <description>• in the mean change in the percentage of patients with an asthma exacerbation during the period from baseline (Visit 1) to the 12 month follow up office visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Device: CREON2000A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Child with mild to moderate asthma maintains allergy medicines and has experimental device installed in home. Will child's use of asthma medicine decrease more than the child who lives with the Device: Sham CREON2000A?</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device: Sham CREON2000A</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Child with mild to moderate asthma maintains allergy medicines and has sham installed in home. What impact will the Device: Sham CREON2000A have and will the child's medical use parallel that of the child with the experimental Device: CREON2000A?</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CREON2000A</intervention_name>
    <arm_group_label>Device: CREON2000A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <arm_group_label>Device: Sham CREON2000A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Males and Females ages 6.0 to 17.0 years.

          2. Subjects with a physician diagnosis of mild or moderate persistent asthma.

          3. FEV1 ≥ 60% predicted with ≥ 12% improvement after bronchodilator therapy.

          4. Must have evidence of; 1) serum specific IgE (immunocap) ≥ .35 or 2) a positive skin
             prick test to one or more common indoor allergens including standardized house dust
             mite, cat, dog, cockroach, mouse in the past.

        Exclusion criteria

          1. Current smokers

          2. Passive exposure to environmental tobacco smoke at home or active fireplaces and other
             sources of air particulates (wood burning stoves, kerosene heaters) at home.

          3. Diagnosed by a physician with a chronic lung disease other than asthma.

          4. Upper or lower respiratory infection within four weeks prior to enrollment.

          5. Known to have any other chronic illness (besides asthma) that is not well controlled
             at the time of screening (Visit 1).

          6. History of a life threatening asthma attack requiring cardiopulmonary support,
             intubation with ventilatory support, hospitalization in an intensive care unit or
             hospitalization for asthma within 6 months preceding study screening (Visit 1).

          7. Participation in another investigational drug/device study within the past 3 months
             (not including chart or observational studies)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Bernstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Cincinnati, Cincinnati, Ohio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Glazman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Innovations and Goods, Inc. (GI&amp;G)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Glazman, PhD</last_name>
    <phone>614-238-9000</phone>
    <email>mglazman@creon2000.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anand Seth, PhD</last_name>
    <phone>614-735-9569</phone>
    <email>anand.seth@creon2000.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Advanced Research Institute of Miami, LLC</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Arechaga</last_name>
    </contact>
    <investigator>
      <last_name>Kunjana Mavunda, MD, MPH, DTM&amp;H</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Associates</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Gribbins, CRC</last_name>
      <phone>859-277-9112</phone>
      <email>amy.gribbins@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>William Greisner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Lierl, MD</last_name>
      <phone>513-636-6771</phone>
      <email>michelle.lierl@CCHMC.org</email>
    </contact>
    <contact_backup>
      <last_name>Shane McKee, MS/CCRP</last_name>
      <phone>513-636-0740</phone>
      <email>shanemckee@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michelle Lierl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Bernstein, RN, BSN, CCRC</last_name>
      <phone>513.931.0775</phone>
      <email>CherylKB@bernsteincrc.com</email>
    </contact>
    <contact_backup>
      <last_name>Karen Murphy, BS, RRT, CCRC</last_name>
      <phone>513.354.1746</phone>
      <email>kmurphy@bernstein.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan A. Bernstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Prince, MD</last_name>
      <phone>614-722-2650</phone>
      <email>Benjamin.Prince@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Katlyn Latimer, CCRN</last_name>
      <phone>614-722-2605</phone>
      <email>Christine.Baker@nationwidechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Benjamin Prince, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Stukus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mitchell Grayson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatric Research Assn.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Schaurer, MA, CRC</last_name>
    </contact>
    <investigator>
      <last_name>Julie Shepard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles W DeBrosse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Winder &amp; Associates Inc.</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Michalak, LPN, CCRP</last_name>
      <phone>419-885-5163</phone>
      <email>mamichalak@buckeye-express.com</email>
    </contact>
    <investigator>
      <last_name>John A Windner, MD, CPI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Lakes Medical Research, LLC</name>
      <address>
        <city>Willoughby</city>
        <state>Ohio</state>
        <zip>44094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhiannon Regal</last_name>
      <phone>440-205-1225</phone>
      <phone_ext>233</phone_ext>
      <email>rregal@glmrx.com</email>
    </contact>
    <contact_backup>
      <last_name>Renee Nerderman, RN CCRC</last_name>
      <phone>440-205-1225</phone>
      <phone_ext>218</phone_ext>
      <email>rnerderman@glmrx.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Lavi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma environment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

